Gateway® Open Architecture Policy

Research efforts are moving from gene acquisition to uncovering gene function and deciphering how specific genes interact on a genome-wide level. With the advent of enhanced technologies, protein analysis can now occur in parallel with genomic characterization. Collaborative efforts and shared resources powered by platform technologies will streamline and accelerate the movement from genomic acquisition to proteomic understanding and the eventual application to disease correlation, drug discovery, and pharmacogenomic disciplines.

Open Access to Gateway® Technology - Encouraging Partnerships for Discovery

Reagent suppliers and corporations need to understand how their technologies play a role within the research and development process. At Invitrogen, we realize and support the need for unrestricted distribution of material for research, discovery, drug, and therapeutic development enabled by our proprietary technologies. One such example is the Gateway® Technology, which allows researchers to build ORF, promoter, and other clone sets for archiving and future access. Based on lambda phage recombination, Gateway® Technology provides a rapid, straightforward approach so that researchers can shuttle clones to a wide variety of applications for further refinement with minimal subcloning.

When it was initially launched in 1999, there were several use restrictions around Gateway® Technology that required additional licensing. These limitations included research use by industrial entities, distribution of research materials by academic investigators, and any commercial use. In 2003, Invitrogen instituted the Gateway® Open Architecture in response to the urgent need of the research communities for open access to Gateway® Technology for scientific research. The majority of genome-wide initiatives are funded by government agencies which require all resources and information, including data, software, and biological materials to be openly accessible. We realized that our policies were too restrictive, and instead of enabling your research with advanced technology, we were impeding it with our interest in protecting intellectual property. Our vision, including strategic business pursuits such as corporate licensing, must align with our customers needs. We believe we share a common quest with you to support and facilitate cutting-edge life science research; thus we have introduced a new open architecture for Gateway® Technology. Under this new licensing policy:

  • Academic and government researchers may create and freely distribute Gateway® entry clones (containing attL1 and attL2 sites) and expression clones (containing attB1 and attB2 sites) for research use without licensing fees or royalties to Invitrogen.
  • Any organization may now freely distribute Gateway® entry clones created by Academic or Government researchers, for research use, without paying licensing fees or royalties to Invitrogen, and may distribute Gateway® expression clones created by Academic or Government researchers, for research use, for a nominal fee of up to $10 per clone.
  • The rights to perform the Gateway® recombinational cloning reaction, for research purposes, with thesedistributed clones is conveyed by the purchase of Gateway® Clonase™ enzyme from Invitrogen.
  • Invitrogen will not assert a claim against the buyer of infringement based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer provided that no method claim in the corresponding patents were used in the manufacture of such product.

We believe that this policy of open access to Gateway® clones for scientific research purposes is the best way for Invitrogen to support your efforts in the advancement of global life sciences. We are committed to ensuring that new information and resources will be accessible to the broader community by first, eliminating unwarranted licensing restrictions and by second, providing the resources necessary as a key distributor and partner.